Check out these blue chip ASX 200 shares…
The post 2 ASX 200 blue chip shares tipped as buys appeared first on The Motley Fool Australia. –
Are you wanting to boost your portfolio with some blue chip ASX 200 shares in July?
Then you might want to look at the blue chips listed below. Here’s what you need to know about them:
Goodman Group (ASX: GMG)
The first blue chip ASX 200 share to look at is Goodman Group. It is a leading integrated commercial and industrial property company with a portfolio of warehouses, large scale logistics facilities, and business and office parks.
Goodman Group has been growing at a solid rate for years thanks to the success of its own+develop+manage model. This model sees Goodman own high quality properties, develop properties in key locations to meet customer needs, and manage the premium real estate it invests in globally.
When it comes to choosing properties, Goodman focuses on investing in and developing high quality industrial properties in strategic locations, close to large urban populations, and in and around major gateway cities globally. It notes that this is where demand is strong and transformational changes are driving significant opportunities for its business.
FY 2021 has been another year of growth for Goodman. Management recently revealed that it expects to achieve its guidance for operating profit of $1.2 billion and earnings per share growth of 12%.
Morgan Stanley is a fan of Goodman. It currently has a buy rating and $23.00 price target on its shares.
ResMed Inc. (ASX: RMD)
Another blue chip ASX 200 share to look at is ResMed. It is a medical device company with a focus on the sleep treatment market.
The sleep treatment market certainly is a great place to be. Management estimates that there are over 1 billion people globally that suffer from sleep apnoea. And with the vast majority of these people yet to be diagnosed, this gives ResMed a significant market opportunity to grow into.
And thanks to its industry-leading products, wide distribution network, and successful acquisitions, ResMed appears well-placed to capture this growing demand over the next decade.
In the near term, ResMed’s growth looks set to be boosted by the upcoming launch of its new CPAP device, AirSense 11, and a significant product recall by a leading rival.
Macquarie is positive on the company and current has an outperform rating and $34.85 price target on its shares.
Should you invest $1,000 in ResMed right now?
Before you consider ResMed, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and ResMed wasn’t one of them.
The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of May 24th 2021
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.